Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 16Nivolumab 9atezolizumab 7Docetaxel 7Cyclophosphamide 5durvalumab 4Ipilimumab 4Gemcitabine 4avelumab 3Specimen Handling 3Radiotherapy 3Psychiatric Rehabilitation 3Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3temsirolimus 2spartalizumab 2sargramostim 2fludarabine 2epacadostat 2enzalutamide 2cabozantinib 2aldesleukin 2abiraterone 2Therapeutics 2Standard of Care 2Radiosurgery 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Dalteparin × Genitourinary × Clear all
NCT00003674 2016-07-13

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
141 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡